Neuralstem to Participate at Cell and Gene Therapy World
22 January 2018 - 11:00PM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem,
will discuss NSI-566, the Company’s stem cell therapy program, at
the Cell and Gene Therapy World at the Hyatt Regency in Miami,
FL. The presentation is scheduled for Wednesday, January 24,
2018 at 4:00pm ET.
Neuralstem’s stem cell therapy product candidate, NSI-566, is a
spinal cord-derived neural stem cell line. Neuralstem recently
completed a Phase 2 clinical evaluation of NSI-566 for the
treatment of Amyotrophic Lateral Sclerosis (ALS). The Company
received orphan designation by the FDA for NSI-566 in ALS and the
molecule has since been evaluated in Phase 1 and Phase 2 safety
studies in 30 patients. The data showed that the intraspinal
transplantation of the cells was safe and well tolerated.
NSI-566 is also being evaluated for the treatment of paralysis
from chronic motor stroke as well as chronic spinal cord injury
(cSCI). Subjects from all three indications are currently in
long-term observational follow-up periods to continue to monitor
safety and possible therapeutic benefits.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. The Company’s lead development candidate,
NSI-189, is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke. NSI-566 is a stem cell therapy
being tested for treatment of paralysis in stroke, chronic spinal
cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS).
Neuralstem’s diversified portfolio of product candidates is based
on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three and nine
months ended September 30, 2017, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Contact:Kimberly MinarovichArgot Partners
(Investor Relations)212-600-1902kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024